Stocktoria
SPRUCE BIOSCIENCES, INC. SPRB
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-10-09
SPRUCE BIOSCIENCES, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $4.9M | $10.1M | $0 | — |
| R&D expense | $19.5M | $46.4M | $49.4M | $35.2M | $30.7M |
| Operating income | -$36.5M | -$56.2M | -$52.0M | -$47.3M | -$42.1M |
| Interest expense | $90,000 | $307,000 | $483,000 | $420,000 | $345,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$39.0M | -$53.0M | -$47.9M | -$46.2M | -$42.3M |
| EPS (diluted) | $-50.83 | $-96.40 | $-1.24 | $-1.96 | $-1.81 |
| Operating cash flow | -$33.3M | $56.0M | $33.3M | $41.7M | $35.9M |
| Free cash flow | — | $56.0M | $33.3M | $41.7M | $35.8M |
| Cash & equivalents | $48.9M | $38.8M | $96.3M | $24.5M | $42.7M |
| Total assets | $53.0M | $45.2M | $103.9M | $85.6M | $126.5M |
| Total liabilities | $10.5M | $16.4M | $27.4M | $17.2M | $15.1M |
| Shareholders' equity | $42.5M | $28.8M | $76.5M | $68.5M | $111.4M |
Source: SEC EDGAR filings · CIK 0001683553 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.